CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 401 enrolled
Drug / intervention
Mometasone Furoate Nasal Spray (MFNS) +1 moredrug
Likely dose
Mometasone Furoate Nasal Spray (MFNS) 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00358527
NCT00358527Phase 4Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis

Organon and Co·interventional·Posted Aug 1, 2006·Updated Feb 8, 2022

In Brief

A Phase 4 clinical trial evaluating Mometasone Furoate Nasal Spray (MFNS) and Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 401 participants.

Detailed Summary

This study will hope to show that by relieving the participant's nasal symptoms of seasonal allergies using mometasone furoate nasal spray, the participant will obtain a better quality of night-time sleep, which in turn, causes less daytime sleepiness so that he/she can function productively during the day.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
CollaboratorsIntegrated Therapeutics Group

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2006
Enrollment StartMay 1, 2006
Primary CompletionOct 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 19.9 years ago

Interventions

Mometasone Furoate Nasal Spray (MFNS)drug

MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.

Placeboother

Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days